Document Detail


Comparison of the effect of perindopril and acebutolol on cerebral hemodynamics in hypertensive patients.
MedLine Citation:
PMID:  11504165     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The aim of the study was to compare effect of perindopril (4 mg once a day) versus acebutolol (400 mg once a day) on cerebral hemodynamics in hypertensive patients. METHODS: Thirty untreated patients with mild-to-moderate hypertension were studied. Drug influences on Doppler-derived parameters from the cerebral blood flow (CBF) velocity wave form were evaluated in a randomized, double blind, cross-over, placebo controlled study. The mean CBF velocity, pulsatility index (PI), cerebrovascular resistance and index of CBF were calculated from concomitant transcranial Doppler measurements and systemic blood pressure. RESULTS: Acebutolol and perindopril significantly decreased systolic, diastolic and mean blood pressure in relation to placebo. The mean value of CBF velocity increased to a comparable level after both drugs (54.9 +/- 9.1 cm/s on placebo vs 62.8 +/- 14.5 cm/s on perindopril p<0.01 and 61.4 +/- 9.2 cm/s on acebutolol, p<0.01). Also, the cerebrovascular resistance index decreased similarly after both drugs (2.26 +/- 0.35 on placebo vs 1.68 +/- 0.42 on perindopril p<0.01 and 1.7 +/- 0.36 on acebutolol p<0.01). The calculated CBF index increased significantly after each drug (25.23 +/- 7.99 on placebo vs 33.98 +/- 11.23 p<0.01 on perindopril and 30.90 +/- 8.04 on acebutolol p<0.01). However, perindopril augmented the CBF index more effectively than acebutolol (p<0.05). CONCLUSIONS: Among patients with mild-to-moderate hypertension both acebutolol and perindopril beneficially decreased cerebrovascular resistance and increased the CBF index in comparison with placebo. The increase of CBF index was greater after perindopril than acebutolol, which suggests a more significant improvement in cerebral perfusion by perindopril. The non-invasive transcranial Doppler ultrasonography method of CBF velocity measurement may contribute to choosing optimal antihypertensive therapies and to monitor their effect.
Authors:
W Pieniazek; P P Dimitrow; T Jasiński
Related Documents :
6615685 - Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension.
6649055 - A comparison of timolol plus hydrochlorothiazide plus amiloride and methyldopa in essen...
1318845 - A comparison of the effect of lisinopril and hydrochlorothiazide on electrolyte balance...
12874615 - Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate e...
17515445 - Trended cosinor change model for analyzing hemodynamic rhythm patterns in hemodialysis ...
6092405 - An endogenous ouabain-like factor associated with hypertensive pregnant women.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  15     ISSN:  0920-3206     ISO Abbreviation:  Cardiovasc Drugs Ther     Publication Date:  2001 Jan 
Date Detail:
Created Date:  2001-08-15     Completed Date:  2002-01-31     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  63-7     Citation Subset:  IM    
Affiliation:
1st Department of Internal Medicine, Collegium Medicum Jagiellonian University, Kraków, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acebutolol / therapeutic use*
Adrenergic beta-Antagonists / therapeutic use*
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Cerebrovascular Circulation / drug effects,  physiology*
Cross-Over Studies
Double-Blind Method
Female
Humans
Hypertension / drug therapy*,  physiopathology
Male
Middle Aged
Perindopril / therapeutic use*
Ultrasonography, Doppler, Transcranial
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 37517-30-9/Acebutolol; 82834-16-0/Perindopril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Myocardial lactate release after intracoronary verapamil application in humans: acute effects of int...
Next Document:  The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure EvaluatioN trial (CARMEN)--rationale...